`
`Purdue Pharma Statement on Abuse and Diversion of OxyContin®
`
`http://www.purduepharma.com:80/pressroom/news/oxycontinNews/160_Statem
`
`Go
`
`2 captures
`21 Oct 2002 - 17 Feb 2003
`
`SEP OCT FEB
`21
`2001 2002 2003
`
`👤 ⍰ ❎
`
`
`f 🐦
`
`▾ About this capture
`
`
`
`Prescribing Information
`
`For Immediate Release
`
`Contact: James W. Heins/Purdue Pharma /203-588-8069
`Statement Regarding Suspension of 160 mg OxyContin®
`Tablets
`
`
`
`Stamford, CT – May 11, 2001 - Purdue Pharma introduced the 160 mg strength
`OxyContin® tablets to help patients suffering from the most severe, persistent pain.
`However, recent media attention has made more people aware of the abuse potential
`of opioid analgesics. Even though there have been few reports of diversion of the
`160 mg tablets, Purdue is concerned about the possibility of illicit use of tablets of
`such high strength.
`
`
`Therefore, we have decided to temporarily suspend shipment of the 160 mg tablets –
`at least until we have studied this issue further. This is voluntary action on Purdue’s
`part. While we regret that our action may burden some patients, we believe strongly
`that on balance our action is the right thing to do.
`
`
`Purdue is working to ensure that patients with legitimate medical need continue to
`have access to OxyContin® tablets, and we remain committed to helping educate the
`medical community about its appropriate use.
`
`
`Purdue Letter to Healthcare Professionals
`OxyContin® Package Insert
`
`
`
`https://web.archive.org/web/20021021055206/http://www.purduepharma.com:80/pressroom/news/oxycontinNews/160_Statement.asp
`
`1/1
`
`Purdue 2013
`Collegium v. Purdue, PGR2018-00048
`
`